Therefore, the duration of growth factor administration is usually related to the definition of myeloid engraftment.
The traditional definition of myeloid engraftment has been the first of 3 consecutive days with an absolute neutrophil count (ANC) of 0.5 Â 10 9 /l or more, to ensure sustained recovery. Thus, growth factors are usually continued until ANC is X0.5 Â 10 9 /l for 3 consecutive days. We have shown that the neutrophil count almost never declines below 0.5 Â 10 9 /l on the 2 consecutive days after having reached that level in blood stem cell autograft 8 and allograft 9 recipients. Based upon this, we modified our definition of myeloid engraftment to the first day with ANC X0.5 Â 10 9 /l; a change that is associated with some logistic benefits. 8 At the same time, since the ANC actually increased several-fold over the 2-3 days following the day of engraftment after autograft, 8 we changed our routine clinical practice to discontinuing growth factor the day the ANC reached 0.5 Â 10 9 /l rather than continuing for an additional 2 days.
This retrospective analysis was undertaken to compare the course of neutrophil recovery in patients who discontinued growth factor, with those who continued growth factor after the first day with ANC X0.5 Â 10 9 /l.
Patients and methods
A total of 153 adult patients with malignant diseases autografted in the Hematopoietic Stem Cell Transplant Program of the Division of Hematology-Oncology of the Feinberg School of Medicine, Northwestern University, and the Northwestern Memorial Hospital between February 1998 and January 2003 were studied. All patients provided informed consent for the transplant procedures, and all research protocols were approved by the Institutional Review Board.
Electronic and paper records were reviewed to obtain all blood counts, whether performed in the hospital laboratory (in-patient), the clinic laboratory (outpatient), or elsewhere (usually immediately after discharge through home health agency services). Whenever multiple blood count results were available for the same day, the morning blood count was included in the analysis and the remaining counts were not studied. ANC included segmented neutrophils as well as bands. Table 1 shows the patient characteristics. The conditioning regimens employed were at standard doses, and included high-dose melphalan (plasma cell dyscrasias), busulfan-etoposide (acute myeloid leukemia), busulfancyclophosphamide (lymphoma), carmustine-etoposide-cytarabine-melphalan (BEAM) (lymphoma, Hodgkin's disease), cyclophosphamide-carboplatin-etoposide with totallymphoid irradiation (Hodgkin's disease), or cyclophosphamide-carboplatin-thiotepa (breast cancer). CD34 þ cell doses were calculated on the basis of the ideal body weight (IBW). 10 Patients did not receive trimethoprimsulfamethoxazole routinely in the immediate post transplant period.
Growth factor administration
After the transplant, 136 patients received filgrastim (G-CSF) and 17 patients received sargramostim (GM-CSF) at the dose of 5-10 mg/kg, subcutaneously daily, until the ANC reached 0.5 Â 10 9 /l, the first day with ANC X0.5 Â 10 9 /l being considered the day of engraftment. The type of growth factor used, unless dictated by a particular protocol, was at the discretion of the physician. The growth factor dose was usually rounded off to the nearest vial size to avoid wastage. Growth factors were usually administered in the late afternoon or evening. Growth factor was discontinued when the ANC reached 0.5 Â 10 9 /l in 45 patients, all treated since May 2002. The last dose of growth factor in these patients was the evening before ANC reached this threshold, and they did not receive any growth factor once ANC reached the threshold. The remaining patients continued growth factor until ANC was X0.5 Â 10 9 /l on 2 consecutive days (an additional day of growth factor; n ¼ 37), on 3 consecutive days (2 additional days of growth factor; n ¼ 30), or 4-5 consecutive days (3-4 additional days of growth factor; n ¼ 41). Most of these patients were treated prior to May 2002.
All patients other than the 45 stopping the growth factor early were to have received 2 additional days of growth factor after reaching ANC X0.5 Â 10 9 /l, allowing for documentation of ANC X0.5 Â 10 9 /l for 3 consecutive days. However, this was not the case for two reasons. Those stopping the growth factor after 1 additional day (n ¼ 37) did so mostly because an additional intra-day blood count done on the day ANC reached 0.5 Â 10 9 /l showed a further increase in ANC. Thus, the growth factor was stopped the next day after seeing a third consecutive ANC count (rather than the third consecutive day) X0.5 Â 10 9 /l. Those continuing growth factor beyond the planned 2 additional days (n ¼ 41) usually did so for one of two reasons. For some hospitalized patients, the order to discontinue growth factor automatically on the third day of ANC X0.5 Â 10 9 /l, written as part of the routine admission order set, did not get implemented on the correct day. For some discharged patients, Home Health nurses or the patients themselves continued administering growth factor when it should have been stopped.
Statistical analysis
Patients receiving growth factor after ANC reached 0.5 Â 10 9 /l were grouped together (n ¼ 108; Control Group), irrespective of the number of additional doses (1) (2) (3) (4) , and were compared to the Study Group (n ¼ 45), which received no growth factor after ANC reached 0.5 Â 10 9 /l. The two groups were compared using the Wilcoxon rank-sum test for continuous variables, and the w 2 test or the Fisher's exact test for categoric variables.
Results
As Table 1 shows, there were some differences between groups. There was a significantly higher proportion of myeloma patients and GM-CSF recipients in those stopping growth factors early. A significantly higher proportion of Study Group patients started the growth factor later. The CD34 þ cell dose was slightly higher and engraftment slightly slower for those stopping growth factor early, but these differences were not statistically significant. The actual growth factor doses used were comparable for both groups. All GM-CSF recipients received 500 mg of the drug. G-CSF recipients in both groups received a median of 480 mg G-CSF (range 300-780). Table 2 and Figure 1 illustrate the patterns of neutrophil recovery. ANC was higher in the Study Group on the day of engraftment, but higher in the Control Group on the subsequent 2 days. The difference was particularly marked on the third day. The magnitude of ANC increase was also greater in the Control Group. A significantly greater proportion of Study Group patients experienced a decline in ANC on the second and third days. However, only in Missing ANC values on day 3 (reflected in the numbers in the last two columns under 'Decline in ANC'). a: 4, b: 8, c: 3, d: 7, e: 3, f:4.
Growth factor duration A Verma et al one patient did the ANC drop below 0.5 Â 10 9 /l, to 0.3 Â 10 9 /l on the second day, but increased to 2 Â 10 9 /l on the third day without growth factor. The magnitude of the rise from the second to the third day suggests that the low count on the second day may simply have been an erroneous count. However, in the absence of any other evidence, it must be assumed that the patient did become neutropenic transiently. Almost 90% of patients in the Study Group had an ANC on the third day, which was higher than that on the first day.
Since the number of patients who received GM-CSF was significantly higher in the Study Group (Table 1) , the data were analyzed after removing these patients. The findings were identical (Table 2) . Confining the analysis only to patients starting growth factor on day 5 post transplant for the sake of uniformity yielded similar results (Table 2) .
Fever requiring institution of broad-spectrum intravenous antibiotic therapy was seen in 40 of 45 patients stopping growth factor early compared with 100 of 108 receiving additional growth factor doses (P ¼ 0.45). Bacteremia was seen in 12 patients (all gram-positive) stopping growth factor early compared with 28 patients (1 gramnegative, 27 gram-positive) receiving additional growth factor doses (P ¼ 0.92).
The duration of stay in the hospital measured from the day of transplant (to eliminate differences emanating from differing durations of the conditioning regimens) was comparable for the two groups: 9-22 days (median 14) for those stopping growth factor early and 8-36 days (median 14) for those receiving additional growth factor doses (P ¼ 0.23).
Discussion
Our data suggest that myeloid recovery is not compromised by discontinuing growth factor as soon as ANC recovers to 0.5 Â 10 9 /l. Thus, it is not necessary to continue growth factors for 2 additional days, as is routine practice. Stopping growth factor early decreases the cost of the transplant modestly without increasing hospital stay. The cost savings for a program performing 100 autografts a year is likely to be approximately $50 000 to $80 000 a year, depending upon growth factor dose and acquisition cost. Other potential benefits may be decreased intensity and frequency of bone pain that some patients experience with growth factor-induced myeloid recovery, avoidance of growth factor-induced fever that is seen in a small proportion of patients, and a decrease in the incidence of the so-called engraftment syndrome. 11 However, it must be recognized that our study could not address these issues. There does not appear to be any obvious disadvantage of stopping growth factor early in terms of longer hospital stay or increased infection rates.
The practical growth factor questions that have been addressed previously include whether to use the growth factor, 1, 2 what growth factor to use, 12 when to start growth factor, 3, 4, 7 and what dose to use. 5, 6 However, how long to continue growth factor has not been studied. We believe our data help provide an answer to this question.
The limitations of this study are the heterogeneity between groups in terms of the growth factor used (G-CSF vs GM-CSF) and the day growth factor was started (day 0 vs day 5), because of its retrospective nature. The type of growth factor used would be expected to affect the time to neutrophil recovery rather than the behavior of the counts, once growth factor administration was stopped. In keeping with this supposition, eliminating GM-CSF-treated patients from the analysis did not change the findings. Similarly, the day of growth factor commencement would also be expected to affect the time to engraftment rather than the course after stopping growth factor. Confining the analysis to patients who started on growth factor on day 5 also did not change the findings. The heterogeneous distribution of the underlying diseases between the two groups is another shortcoming; however, it would not be expected to affect the end point being studied here.
As Table 2 and Figure 1 show, the rate of rise of ANC is less steep if growth factor is discontinued, and, in those continuing the growth factor, ANC levels can reach very high levels. There are no data to suggest that such high ANC levels have any beneficial impact on outcome. This suggests that the amount of growth factors administered routinely may be in excess of what is required.
We have shown previously that myeloid recovery after autotransplants is usually robust, and ANC rarely drops below 0.5 Â 10 9 /l, after having reached that threshold in patients continuing the growth factor. 8 The results of this study confirm this observation in patients who discontinue growth factor.
We suggest that growth factors be stopped in autotransplant recipients once the neutrophil count recovers to 0.5 Â 10 9 /l. Growth factor duration A Verma et al
